Eli Lilly's diabetes drug Mounjaro demonstrates an 8% greater reduction in major adverse cardiovascular events compared to its older GLP-1 drug Trulicity in a large trial, strengthening Lilly's position in the competitive GLP-1 market.
Fed holds rates, signals delay on possible cuts amid economic data uncertainty and internal divisions.
Eli Lilly's diabetes drug Mounjaro demonstrates an 8% greater reduction in major adverse cardiovascular events compared to its older GLP-1 drug Trulicity in a large trial, strengthening Lilly's position in the competitive GLP-1 market.
Fed holds rates, signals delay on possible cuts amid economic data uncertainty and internal divisions.